Response to litigation

Oxford Nanopore Technologies, the UK-based company that sells the only nanopore sequencing device, the MinION portable DNA sequencer and is developing the high throughput/ high sample number PromethION device, responds to the patent lawsuit filed by Illumina, Inc. 


Dr Gordon Sanghera, CEO of Oxford Nanopore said "It is gratifying to have the commercial relevance of Oxford Nanopore products so publicly acknowledged by the market monopolist for NGS."

We do not anticipate any disruption to our ongoing commercial progress as a result of Illumina's action, which we believe is without merit.

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.